Table 2.
Psychological, clinical, and biochemical parameters in prostate cancer therapy subgroups
| Parameter (ref value) | Total (n=100) | Prostatectomy only (n=77) | Prostatectomy and adjuvant treatment (n=23) | Cohen’s d | p-value |
|---|---|---|---|---|---|
| HADS-Anxiety | 3.0 (1.0–7.0) | 3.0 (1.0–6.0) | 5.0 (3.0–9.0) | 0.70 | 0.01 |
| HADS-Depression | 3.0 (1.0–6.0) | 2.0 (1.0–4.0) | 4.0 (2.0–8.0) | 0.77 | 0.027 |
| ICIQ-total | 3.0 (0.0–8.0) | 2.0 (0.0–7.0) | 7.0 (0.0–13.0) | 1.1 | 0.045 |
| IIEF-5 | 0.0 (0.0–7.0) | 0.0 (0.0–8.0) | 0.0 (0.0–5.0) | 0.61 | 0.31 |
| PSA-1 (<4.1 ng/mL) | 7.5 (5.4–10.6) | 7.1 (5.2–9.3) | 10.3 (6.4–17.0) | 0.8 | 0.035 |
| PSA-2 (<4.1 ng/mL) | 0.003 (0.003–0.037) | 0.003 (0.003–0.017) | 0.008 (0.003–0.14) | 0.09 | 0.045 |
| Testosterone (1.23–8.92 ng/mL) | 4.63 (3.15–6.26) | 5.2 (3.49–6.4) | 3.56 (2.47–4.5) | 0.70 | 0.001 |
Notes: Data are shown as the median (25th–75th quartile). Inter-group differences were assessed using the Mann–Whitney U-test. Effect size was measured using the Cohen’s d method. Significant p-values are shown in bold.
Abbreviations: HADS, Hospital Anxiety and Depression Scale; ICIQ, International Consultation on Incontinence Modular Questionnaire; IIEF-5, International Index of Erectile Function; PSA, prostate-specific antigen; Ref value, reference values.